摘要
目的建立血浆和血细胞中砷(Ⅲ)的气相色谱测定方法,考察小鼠静脉注射砷(Ⅲ)溶液后血浆和血细胞中的药动学情况。方法血浆样品经6%高氯酸去蛋白,二巯基丙醇(BAL)衍生化后,苯萃取,浓缩后用苯溶解后进样,血细胞样品则直接衍生化后经苯萃取、浓缩、再溶解后进行GC分析。采用该方法测定给小鼠静脉注射砷(Ⅲ)后血浆和血细胞中砷(Ⅲ)浓度,计算主要的药动学参数。结果血浆和血细胞中砷(Ⅲ)分别在0.0375~2.40和0.03125~1.00mg·L-1内线性关系良好,两者的t1/2α分别是7.178和2.531min,t1/2β分别为108.731和146.236min,AUC0-∞则分别为72.334和112.239mg.min·L-1。结论本实验建立的小鼠血样中砷的气相色谱测定法设备简单方便、方法灵敏可靠,砷在小鼠血浆和血细胞中的消除很快,没有蓄积的倾向,而血细胞中砷的浓度要高于血浆中的浓度。
Abstract
OBJECTIVE To develop a GC method for the determination of As(Ⅲ) in mouse plasma and red blood cells and to investigate the pharmacokinetics of As(Ⅲ) in mice after an intravenous injection of arsenite solutions.METHODS After being deproteined by 6% HClO4,derivatized with 2,3-dimer-captopropanol (BAL),extracted by benzene,dried by N2,and redissolved in 0.1 mL benzene,plasma samples were separated by GC. Red blood cells were directly derivatized and injected after the same process. Mouse blood samples were collected at different time points by extirpating eyeball after intravenous injection,determined by established GC determination methods.The main pharmacokinetic parameters were determined thereby.RESULTS Calibration curves of As(Ⅲ) in plasma and red blood cells were both linear in the ranges of 0.037 5~2.40 and 0.031 25~1.00 mg·L-1 respectively.t1/2α were respectively 7.178 and 2.531 min,t1/2β were 108.731 and 146.236 min,AUC0-∞ were 72.334 and 112.239 mg·min·L-1。CONCLUSION GC method for the determination of As(Ⅲ) in blood samples is sensitive,reliable and simple As(Ⅲ) Elimination in plasma and red blood cells is rapid,and had no cumulation trend.As(Ⅲ) concentration in mice red blood cells is higher than that in plasma.
关键词
砷(Ⅲ) /
气相色谱法 /
血浆 /
血细胞
{{custom_keyword}} /
Key words
arsenic /
GC method /
plasma /
red blood cells
{{custom_keyword}} /
李士敏;朱亚尔;李俊.
GC测定砷(Ⅲ)在小鼠血浆和血细胞中的浓度及药动学研究[J]. 中国药学杂志, 2007, 42(14): 1084-1086
LI Shi-min;ZHU Y-er;LI Jun .
Determination of As(Ⅲ) in Plasma and Red Blood Cells by GC and Its Pharmacokinetic Analysis in Mice [J]. Chinese Pharmaceutical Journal, 2007, 42(14): 1084-1086
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] NI J Y,CHEN G Q,SHEN Z X,et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia[J] .Chin J Hematol(中华血液学杂志),1997,18(5):250-253.
[2] GUO Y,QIAO Z H. Reserarch advance on the use of arsenic trioxide (AS2O3 ) in the treatment of acute p romyelocytic leukemia[J] .Proc Clin Med(临床医药实践),2005,14(2):87-90.
[3] ZHANG R,ZHI Y J,TAO R F,et al. Arsenic trioxide therapy for chronic myelogenous leukemia in accelerated phase[J] .Chin Clin Oncol(临床肿瘤学杂志),2000,5(4):263-265.
[4] QIN Y,LIU H W. Determination of the Arsenic in Plasma and Urine by Gas chromatography[J] .Acta Unniv Med Second Shanghai(上海第二医科大学学报),1998,18(3):216-217.
[5] KNOWLES F C,BENSON A A,The biochemistry of arsenic[J] . Trends Biochem Sci,1983,8:178-180.
[6] KONG X R.Nutritious,Physiological and Clinical Effects of Trace Eelement[M] .He Fei:Anhui Technological Publish Company,1982:394.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}